Sunday , December 17 2017
Home / Therapies / SGLT-2 Therapy Center (page 19)

SGLT-2 Therapy Center

Diabetes in Control is pleased to provide you with the latest insights and information on the Sodium-Dependent Glucose Transporter Two (SGLT-2) drug class to help optimize your practice. We hope you’ll benefit from the insights and share them with your colleagues. Thanks for all you’re doing to improve your patients’ lives and longevity!

SGLT2 Inhibitor Approvals and Updates

Johnson & Johnson’s SGLT2 canagliflozin (Invokana) has just received FDA approval, while Boehringer Ingelheim and Eli Lilly submit their SGLT2 inhibitor (empagliflozin) to the FDA…. U.S. health regulators have approved a new diabetes drug from Johnson & Johnson, making it the first in its class to be approved in the United States. …

Read More »

SGLT Inhibitors

630-F1a

History of the sodium-glucose co-transporter (SGLT) inhibitors by Erica Paul, PharmD, Graduate Intern University of Florida College of Pharmacy Back in the late 1800’s, a compound called phlorizin, found in the bark of apple trees, was isolated by French chemists. Since then it has been put to use in multiple …

Read More »

Stop Using Sulfonylureas?

The ACP has issued a clinical practice guideline regarding use of oral agents in type 2 diabetes entitled, “Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline From the American College of Physicians.”… This is important because despite new therapies, there hasn’t been a guideline from either …

Read More »

Possible New Therapy for Type 2 Diabetes

Inhibitors Of The Novel Target Sodium-dependent Glucose (co-) Transporter (SGLT) For Therapy Of Type 2 Diabetes A plethora of SGLT inhibitors in the patent literature and seven compounds in early clinical development indicate an abundance of interest in the therapeutic use of SGLT inhibitors for the treatment of type 2 …

Read More »